Abstract:A strategy is presented to augment the protein degradation capability of proteolysis targeting chimeras (PROTACs) by modulating external nutrient supply and employing nanocarrier‐based targeted delivery. The results demonstrate that a reduction in nutrient supply can enhance protein metabolism and significantly improve the therapeutic efficacy of PROTACs when combined with nanocarriers. The ubiquitin‐proteasome system (UPS) is responsible for degrading over 70–80% of cellular proteins. Consequently, proteolysis‐targeting chimeras (PROTACs) are developed to induce the ubiquitination and subsequent degradation of proteins of interest (POIs) by the UPS. To amplify the therapeutic efficacy of PROTACs, energy metabolism regulation is first harnessed to boost UPS function in tumor cells. Proteomic and ubiquitinome analyzes reveal that total ubiquitinated proteins and proteasome activity are significantly increased in 143B and MDA‐MB‐231 tumor cells following fasting‐mimicking diet (FMD) treatment. As a result, the degradation efficiency of PROTACs targeting focal adhesion kinase (FAK‐P) or bromodomain‐containing protein 4 (BRD4‐P) is significantly enhanced in FMD‐treated 143B and MDA‐MB‐231 tumor cells. Then, silica‐coated iron oxide nanoparticles are developed modified with tumor cell membranes for targeted delivery of PROTACs. Magnetic resonance imaging (MRI) and fluorescence imaging confirm that nanocarriers significantly improve the delivery efficiency of PROTACs in FMD‐treated 143B or MDA‐MB‐231 tumors. In vivo studies demonstrate that the antitumor efficacy of FAK‐P and BRD4‐P is greatly augmented when combined with targeted delivery and FMD treatment. Overall, this study presents a strategy to enhance the efficacy of PROTACs in cancer therapy.

Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo.

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Augmenting Protein Degradation Capacity of PROTAC through Energy Metabolism Regulation and Targeted Drug Delivery

Cancer Selective Target Degradation By Folate-Caged Protacs

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Selective Protein of Interest Degradation Through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Amphiphilic Affibody-Protac Conjugate Self-Assembled Nanoagents for Targeted Cancer Therapy

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Aptamer-PROTAC Conjugates (APCs) for Tumor-specific Targeting in Breast Cancer.

PROTACs in gastrointestinal cancers

Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation

Sulfatase-Induced in Situ Formulation of Antineoplastic Supra-PROTACs

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment